Report overview
Recombinant Human Serum Albumin (Rec. HSA) is animal origin free expressed in E.coli without animal or human derived raw materials. It is also free from other contaminating serum proteins.
Recombinant human serum albumin (rHSA) is genetically engineered and derived from a rice-based expression system. It is a highly purified and completely animal-, virus-, and bacteria-free product that was developed as an alternative to plasma-derived HSA, to which it is structurally equivalent.
This report contains market size and forecasts of Recombinant Human Serum Albumin in global, including the following market information:
Global Recombinant Human Serum Albumin Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global Recombinant Human Serum Albumin Market Sales, 2018-2023, 2023-2030, (Kg)
Global top five Recombinant Human Serum Albumin companies in 2022 (%)
The global Recombinant Human Serum Albumin market was valued at 72 million in 2022 and is projected to reach US$ 114.1 million by 2030, at a CAGR of 6.9% during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
OsrHSA Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Recombinant Human Serum Albumin include Albumedix, Merck, Ventria (InVitria), NCPC, Oryzogen and HiMedia, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Recombinant Human Serum Albumin manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Human Serum Albumin Market, by Type, 2018-2023, 2023-2030 ($ Millions) & (Kg)
Global Recombinant Human Serum Albumin Market Segment Percentages, by Type, 2022 (%)
OsrHSA
ScrHSA
Global Recombinant Human Serum Albumin Market, by Application, 2018-2023, 2023-2030 ($ Millions) & (Kg)
Global Recombinant Human Serum Albumin Market Segment Percentages, by Application, 2022 (%)
Cell Culture Media
Medical Supplements
Other
Global Recombinant Human Serum Albumin Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions) & (Kg)
Global Recombinant Human Serum Albumin Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Human Serum Albumin revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Recombinant Human Serum Albumin revenues share in global market, 2022 (%)
Key companies Recombinant Human Serum Albumin sales in global market, 2018-2023 (Estimated), (Kg)
Key companies Recombinant Human Serum Albumin sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Albumedix
Merck
Ventria (InVitria)
NCPC
Oryzogen
HiMedia
